Cargando…

Unique Predictors of Mortality in Patients With Pulmonary Arterial Hypertension Associated With Systemic Sclerosis in the REVEAL Registry

BACKGROUND: Patients with pulmonary arterial hypertension (PAH) associated with systemic sclerosis (SSc-APAH) experience higher mortality rates than patients with idiopathic disease and those with other connective tissue diseases (CTD-APAH). We sought to identify unique predictors of mortality assoc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chung, Lorinda, Farber, Harrison W., Benza, Raymond, Miller, Dave P., Parsons, Lori, Hassoun, Paul M., McGoon, Michael, Nicolls, Mark R., Zamanian, Roham T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American College of Chest Physicians 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251613/ https://www.ncbi.nlm.nih.gov/pubmed/24992469 http://dx.doi.org/10.1378/chest.13-3014

Ejemplares similares

Characterization of First-Time Hospitalizations in Patients With Newly Diagnosed Pulmonary Arterial Hypertension in the REVEAL Registry
por: Burger, Charles D., et al.
Publicado: (2014)

Prediction of patient outcomes through social determinants of health: The Pulmonary Hypertension Association Registry (PHAR) evaluation
por: Grinnan, Dan, et al.
Publicado: (2022)

Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series
por: Raina, Amresh, et al.
Publicado: (2017)

Reply to Andréasson et al.: Multiple Manifestations of Systemic Sclerosis Affect Walk Distance
por: Zamanian, Roham T., et al.
Publicado: (2021)

Non-invasive right ventricular load adaptability indices in patients with scleroderma-associated pulmonary arterial hypertension
por: French, Sarah, et al.
Publicado: (2018)

Risk assessment in patients with pulmonary arterial hypertension in the era of COVID 19 pandemic and the telehealth revolution: State of the art review
por: Wesley Milks, Michael, et al.
Publicado: (2021)

Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Humbert, Marc, et al.
Publicado: (2019)

Novel composite clinical endpoints and risk scores used in clinical trials in pulmonary arterial hypertension
por: Sitbon, Olivier, et al.
Publicado: (2020)

Hit Early and Hit Hard in Pulmonary Arterial Hypertension? Not So Fast!
por: Hassoun, Paul M., et al.
Publicado: (2021)

United States Pulmonary Hypertension Scientific Registry (USPHSR): rationale, design, and clinical implications
por: Elliott, C. Gregory, et al.
Publicado: (2019)

The importance of patient perspectives in pulmonary hypertension
por: McGoon, Michael D., et al.
Publicado: (2019)

Diagnosis and management of pulmonary hypertension associated with left ventricular diastolic dysfunction
por: Perez, Vinicio A. de Jesus, et al.
Publicado: (2012)

The Evolution of Risk Assessment in Pulmonary Arterial Hypertension
por: Murthy, Sandhya, et al.
Publicado: (2021)

The Role of Neutrophils and Neutrophil Elastase in Pulmonary Arterial Hypertension
por: Taylor, Shalina, et al.
Publicado: (2018)

Systemic Sclerosis-Associated Pulmonary Hypertension: Spectrum and Impact
por: Naranjo, Mario, et al.
Publicado: (2021)

Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL)
por: Preston, Ioana R., et al.
Publicado: (2015)

Phenotyping pulmonary hypertension in systemic sclerosis: a moving target
por: Mercurio, Valentina, et al.
Publicado: (2018)

Clinical features of pulmonary arterial hypertension associated with systemic sclerosis
por: Tuhy, Tijana, et al.
Publicado: (2023)

TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension
por: Frantz, Robert P., et al.
Publicado: (2021)

Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension
por: Benza, Raymond L., et al.
Publicado: (2021)

Echocardiographic evaluations of right ventriculo–arterial coupling in experimental and clinical pulmonary hypertension
por: Boulate, David, et al.
Publicado: (2019)

Severe Pulmonary Arterial Hypertension Is Characterized by Increased Neutrophil Elastase and Relative Elafin Deficiency
por: Sweatt, Andrew J., et al.
Publicado: (2021)

Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Benza, Raymond L., et al.
Publicado: (2022)

Safety and efficacy of transitioning from the combination of bosentan and sildenafil to alternative therapy in patients with pulmonary arterial hypertension
por: Verlinden, Nathan J., et al.
Publicado: (2020)

The United States Chronic Thromboembolic Pulmonary Hypertension Registry: Protocol for a Prospective, Longitudinal Study
por: Kerr, Kim M, et al.
Publicado: (2021)

Care of patients with pulmonary arterial hypertension during the coronavirus (COVID-19) pandemic
por: Ryan, John J., et al.
Publicado: (2020)

Phosphodiesterase type 5 inhibitor to riociguat transition is associated with hemodynamic and symptomatic improvement in pulmonary hypertension
por: Davey, Ryan, et al.
Publicado: (2017)

Exome data clouds the pathogenicity of genetic variants in Pulmonary Arterial Hypertension
por: Abbasi, Yeganeh, et al.
Publicado: (2018)

Digital Ischemic Loss in Systemic Sclerosis
por: Marvi, Umaima, et al.
Publicado: (2010)

A case of recurrent pericardial constriction presenting with severe pulmonary hypertension
por: Brunner, Nathan W., et al.
Publicado: (2013)

Myocardial bridge: an unrecognized cause of chest pain in pulmonary arterial hypertension
por: Rajmohan, Divya, et al.
Publicado: (2020)

Serum biomarker for diagnostic evaluation of pulmonary arterial hypertension in systemic sclerosis
por: Rice, Lisa M., et al.
Publicado: (2018)

Limited Systemic Sclerosis Patients with Pulmonary Arterial Hypertension Show Biomarkers of Inflammation and Vascular Injury
por: Pendergrass, Sarah A., et al.
Publicado: (2010)

Impact of the National Amyotrophic Lateral Sclerosis Registry: Analysis of Registry‐funded Research
por: Rechtman, Lindsay, et al.
Publicado: (2022)

Characteristics and predictors of progression in an Egyptian multiple sclerosis cohort: a multicenter registry study
por: Hamdy, Sherif M, et al.
Publicado: (2017)

Early intervention in the management of pulmonary arterial hypertension: clinical and economic outcomes
por: Burger, Charles D, et al.
Publicado: (2017)

Outpatient Inhaled Nitric Oxide in a Patient with Vasoreactive Idiopathic Pulmonary Arterial Hypertension and COVID-19 Infection
por: Zamanian, Roham T., et al.
Publicado: (2020)

Pulmonary Vein Sign on Computed Tomography Pulmonary Angiography in Proximal and Distal Chronic Thromboembolic Pulmonary Hypertension With Hemodynamic Correlation
por: Gopalan, Deepa, et al.
Publicado: (2023)

Correction: Serum biomarker for diagnostic evaluation of pulmonary arterial hypertension in systemic sclerosis
por: Rice, Lisa M., et al.
Publicado: (2022)

Systemic Sclerosis 2011
por: Chung, Lorinda, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_oh2bnsmb41rbistt1g4at2j78h